Navigation Links
Easy-to-use blood thinners likely to replace Coumadin
Date:2/6/2012

MAYWOOD, Ill. -- Within a few years, a new generation of easy-to-use blood-thinning drugs will likely replace Coumadin for patients with irregular heartbeats who are at risk for stroke, according to a journal article by Loyola University Medical Center physicians.

Unlike Coumadin, the new drugs do not require patients to come in to the clinic on a regular basis to check the dose. Nor do the drugs require extensive dietary restrictions.

First author Sarkis Morales-Vidal, MD, and colleagues describe the new drugs in a review article in the February issue of the journal Expert Reviews. Co-authors are Michael J. Schneck, MD, Murray Flaster, MD, and Jos Biller, MD. All are in the Department of Neurology, Stroke Program, of Loyola University Chicago Stritch School of Medicine. Biller is department chair.

The new drugs include rivaroxaban (Xarelto), dabigatran etexilate (Pradaxa) and apixaban (Eliquis). They do not share the disadvantages of Coumadin, and may provide equal or superior prevention against clots, Morales and colleagues write.

Atrial fibrillation is the most common form of irregular heartbeat, and a major cause of stroke in the elderly. Electrical signals, which regulate the heartbeat, become erratic. Instead of beating regularly, the upper chambers of the heart quiver. Not all the blood gets pumped out, so clots can form. The clots can migrate to the brain and cause strokes.

More than 3 million Americans have atrial fibrillation, and the number is increasing, due in part to the aging population.

Coumadin's generic name is warfarin. For more than 30 years, the drug had been the only anticoagulant for primary and secondary stroke prevention in patients with atrial fibrillation. But the Food and Drug Administration recently approved dabigatran and rivaroxaban to reduce the risk of stroke and blood clots in patients with atrial fibrillation that is not caused by a heart valve problem. The FDA is considering an application to approve apixaban for the same use.

Coumadin must be carefully monitored. If the dose is too high, a patient could experience excessive bruising and be at higher risk for brain hemorrhages. If the dose is too low, the drug would be ineffective in preventing blood clots. Patients typically must come in at least once a month for a blood test to determine whether the dose needs to be adjusted. Some patients have to come in as often as twice a week.

Coumadin patients also must restrict their diets. For example, they should consume only small amounts of cranberry juice and alcohol and not eat large amounts of foods that are rich in vitamin K, such as spinach, brussels sprouts and green tea.

Disadvantages of the new medications include the limited clinical experience and lack of antidotes, the researchers wrote. The newer drugs are more expensive than Coumadin, but reduce the cost of patient monitoring and blood testing, Morales said.

Dabigatran is an effective alternative to Coumadin for stroke prevention in patients with non-valvular atrial fibrillation. Rivaroxaban is another promising alternative for those patients. Apixaban appears to be better than aspirin for stroke prevention in atrial fibrillation patients who are not candidates for Coumadin therapy, Morales and colleagues wrote.

The authors predict that within the next few years, the new drugs will likely replace Coumadin for long-term anticoagulation in selective patients with non-valvular atrial fibrillation.


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. Inflammatory Bowel Ups Risk for Blood Clots
2. Bowel disease link to blood clots
3. Local Blood Supply Impacted by Wednesdays Severe Snow Storm
4. PERSONALABS Offers Discounted Healthy Heart Online Blood Tests in February
5. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
6. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
7. Bilberry Seems to Act Against Blood Sugar
8. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
9. UCR researcher identifies mechanism malaria parasite uses to spread in red blood cells
10. NHLBI, CDC launch surveillance and research program for inherited blood diseases
11. IOM report declares high blood pressure a neglected disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology: